Enbrel Biosimilar(L&J Bio)

N/A

Report date: 2024/08/23 17:35:37

Base Information

Drug NameEnbrel Biosimilar(L&J Bio)
Drug Alias NameL&J-EB
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor α inhibitorsTumor necrosis factor β inhibitors
TargetsTumor necrosis factor αTumor necrosis factor β
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesL&J Bio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesL&J Bio Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A